A model for cancer-suppressive inflammation

Ole Audun Werner Haabeth, Bjarne Bogen and Alexandre Corthay

Keywords: cancer, inflammation, M1 macrophages, proinflammatory cytokines, Th1 cells

Introduction

In oncology, inflammation is generally regarded as a cancer-promoting process only. Here, we argue that this view may represent a misleading oversimplification. We present evidence from our own work and from the literature documenting cancer-suppressive aspects of inflammation. We propose that specific types of inflammation, in particular inflammation driven by tumor-specific Th1 cells, may repress rather than promote cancer. Th1 cells collaborate with tumor-infiltrating M1 macrophages to efficiently recognize and eliminate malignant cells. In a Th1 environment, pro-inflammatory cytokines such as interleukin (IL)-1α, IL-1β, IL-6 and tumor-necrosis factor α (TNFα) enhance anti-cancer immunity. Inducing Th1-type inflammation may significantly improve immunotherapeutic strategies against cancer.

We investigated the mechanisms of cancer prevention mediated by tumor-specific CD4+ T cells in mouse models for myeloma and B-cell lymphoma. We used T-cell receptor (TCR) transgenic mice in which all CD4+ T cells recognize a tumor-specific, immunoglobulin-derived antigen that is secreted by the MOPC315 myeloma as well as by the F9 B-cell lymphoma. Tumor-specific TCR-transgenic mice are resistant against subcutaneous challenge with MOPC315 or F9 cells. Protection was shown to be antigen-specific, CD4+ T-cell mediated and independent of B cells and CD8+ T cells. Successful cancer elimination required antigen secretion by malignant cells, and migration of effector CD4+ T cells from the draining lymph node to the incipient tumor site. To study the mechanisms of cancer rejection by TCR-transgenic mice, we developed a strategy consisting of embedding injected tumor cells in a collagen gel. This method allowed us to analyze infiltrating immune cells and to quantify the cytokines that were secreted locally during a primary antitumor immune response. Using this technique, we uncovered a common core of nine cytokines that were consistently present at higher levels in oncology, inflammation is generally regarded as a cancer-promoting process only. Here, we argue that this view may represent a misleading oversimplification. We present evidence from our own work and from the literature documenting cancer-suppressive aspects of inflammation. We propose that specific types of inflammation, in particular inflammation driven by tumor-specific Th1 cells, may repress rather than promote cancer. Th1 cells collaborate with tumor-infiltrating M1 macrophages to efficiently recognize and eliminate malignant cells. In a Th1 environment, pro-inflammatory cytokines such as interleukin (IL)-1α, IL-1β, IL-6 and tumor-necrosis factor α (TNFα) enhance anti-cancer immunity. Inducing Th1-type inflammation may significantly improve immunotherapeutic strategies against cancer.

Here, we argue that the general view that inflammation promotes cancer may represent a misleading oversimplification. We review published evidence in support of cancer-suppressive properties of inflammatory cells and of the canonical pro-inflammatory cytokines IL-1α, IL-1β, IL-6 and TNFα. This leads us to propose a model in which certain types of inflammation, in particular inflammation driven by tumor-specific Th1 cells, may repress rather than promote cancer.

Fig. 1

Th1-Driven Inflammation Protects Mice Against B-Cell Cancer

Inflammation is an immunological process which is essential for the elimination of invading pathogens as well as for wound healing. Inflammation may be considered to be the normal response of the body to harmful stimuli. At cellular and molecular levels, characteristic features of inflammation include increased movement of plasma and leukocytes from the blood into the injured tissue, and production of pro-inflammatory cytokines such as interleukin (IL)-1α, IL-1β, IL-6 and tumor-necrosis factor α (TNFα). A number of studies have demonstrated a link between inflammation and cancer development (reviewed in refs. 1–4). For instance, high IL-6 serum levels have been associated with shorter survival in patients affected by multiple myeloma, lymphoma and lung cancer. Chronic inflammatory diseases like ulcerative colitis, gastritis and rheumatoid arthritis predispose to colorectal cancer. Furthermore, circumstantial evidence suggests that individuals taking non-steroidal anti-inflammatory drugs such as aspirin may have a reduced risk for cancer. Based on these observations, inflammation is widely considered to be detrimental in terms of cancer occurrence, growth and metastasis. Accordingly, dampening inflammation has been suggested as a novel strategy to fight cancer.

Here, we argue that the general view that inflammation promotes cancer may represent a misleading oversimplification. We review published evidence in support of cancer-suppressive properties of inflammatory cells and of the canonical pro-inflammatory cytokines IL-1α, IL-1β, IL-6 and TNFα. This leads us to propose a model in which certain types of inflammation, in particular inflammation driven by tumor-specific Th1 cells, may repress rather than promote cancer.

Fig. 1

A High Density of Immune Cells in Human Primary Tumors Predicts Longer Patient Survival

Infiltration of a tissue by blood-derived leukocytes such as T cells and macrophages, the so-called inflammatory infiltrate, is a typical histological feature of inflammation. It is well known that
solid tumors are infiltrated by various numbers of immune cells, which is consistent with an inflammatory reaction taking place within and around tumors. For many types of human cancer, an association has been demonstrated between dense leukocyte infiltrates in primary tumors and longer patient survival. Infiltration of the primary tumor by undefined inflammatory cells predicted longer survival of patients with skin, colorectal, bladder and breast cancer. Elevated numbers of intratumoral T cells were shown to correlate with longer survival in patients with ovarian, esophageal, lung, colorectal and breast cancer. The presence of both CD8+ and CD4+ T cells positively influenced survival, suggesting that both cell types cooperate to exert anticancer effects. High numbers of CD4+ T cells in lymph nodes predicted disease-free survival in breast cancer. Among CD4+ T cell subsets, Th1 cells seem to be particularly beneficial, as reported for colorectal, liver and breast cancer. Furthermore, a high density of tumor infiltrating macrophages was associated with prolonged survival in prostate, colorectal and lung cancer. Thus, for various types of human cancer, stronger inflammation in the primary tumor, as defined by a high density of infiltrating T cells and macrophages, represents an independent predictor for longer patient survival.

Cancer-Suppressive Functions of IL-1α and IL-1β

IL-1α and IL-1β are two canonical pro-inflammatory cytokines that are typically secreted by activated macrophages. IL-1α and IL-1β have a number of important immunological functions, which are likely to contribute to successful antitumor immunity (Fig. 2). In line with their original name, namely lymphocyte activating factor, both IL-1α and IL-1β are potent stimulators for all leukocytes. For instance, IL-1α and IL-1β synergize with IL-2 to stimulate the proliferation of CD4+ T cells, CD8+ T cells and natural killer (NK) cells. Both IL-1α and IL-1β enhance the expansion and differentiation of CD4+ T cells. IL-1 also stimulates B-cell proliferation, generation of plasma cells and antibody production. Furthermore, IL-1α and IL-1β increase the expression of adhesion molecules on vascular endothelium, which may promote extravasation, i.e., the migration of leukocytes from the bloodstream into the inflamed tissue.

Although tumor-promoting effects of IL-1α and IL-1β are well documented, in particular during cancer metastasis and tumor angiogenesis, a number of studies provide experimental support for cancer-suppressive functions of these two cytokines (Fig. 2). IL-1 was shown to inhibit the proliferation of human A375 melanoma and mouse L929 fibroblast cell lines in vitro. IL-1 rendered human monocytes cytotoxic against a murine fibrosarcoma cell line. Intratumoral injection of IL-1α successfully cured mice from MethA sarcoma and B16 melanoma. IL-1α injected intramuscularly was effective in reducing the number of lung metastases in mice with Lewis lung carcinoma. Intraperitoneal injection of IL-1β caused complete regression of subcutaneous SA1 sarcoma and L5178Y lymphoma in mice. Because IL-1β lost its therapeutic effects in T-cell deficient mice, it was concluded that IL-1β functions by stimulating T-cell mediated antitumor immunity. Activated invasive RO1 T-lymphoma cells that displayed short-term IL-1α expression manifested reduced tumorigenicity and

Figure 1. Successful immunosurveillance of B-cell cancer in mice consists of an inflammatory reaction driven by tumor-specific Th1 cells. Eradication of myeloma and lymphoma in mice is achieved through a collaboration between tumor-specific Th1 cells and tumor-infiltrating, antigen-presenting M1 macrophages. During this process, nine cytokines are secreted locally by immune cells, including pro-inflammatory (IL-1α, IL-1β and IL-6) and Th1-associated cytokines (IL-12 and IFNγ). Th1 cells induce secretion of IL-1α, IL-1β, IL-6, CXCL-9 and CXCL-10 by inflammatory M1 macrophages. Th1-derived IFNγ renders macrophages directly cytotoxic to cancer cells. (Figure modified from ref. 19).

Figure 2. Cancer-suppressive properties of IL-1α and IL-1β. IL-1α and IL-1β synergize with IL-2 to stimulate the proliferation of CD4+ T cells, CD8+ T cells and NK cells; enhance the expansion and differentiation of CD4+ T cells; stimulate B-cell proliferation, generation of plasma cells and antibody production; induce the expression of adhesion molecules on vascular endothelium, which promotes extravasation of leukocytes into the inflamed tissue; directly inhibit the proliferation of specific cancer cells; render human macrophages cytotoxic to some cancer cells; and they amplify antigen-presenting functions and cytokine production by dendritic cells. Ab, antibody; APC, antigen-presenting cell; B, B cell; CD4, CD4+ T cell; CD8, CD8+ T cell; DC, dendritic cell; EC, endothelial cell; MΦ, macrophage; NK, natural killer cell.
could be used to treat mice with lymphoma. Similarly, fibrosarcoma cells transfected with IL-1α became strongly immunogenic and failed to generate tumors in mice. Notably, IL-1β secretion is dependent on activation of the NLRP3 inflammasome, a cytosolic molecular complex responsible for generating active IL-1β by cleaving the inactive precursor. The NLRP3 inflammasome has been demonstrated to protect mice against colitis-associated cancer. Furthermore, in mouse models for cancer chemotherapy, activation of the NLRP3 inflammasome in dendritic cells appears to be essential for the induction of IL-1β-dependent adaptive antitumor immunity. In line with these experimental findings, a genetic analysis of multiple myeloma patients revealed that individuals with a polymorphism in the promoter region of the IL-1B gene, leading to reduced IL-1β production, had significantly shorter survival after chemotherapy. Thus, antitumor effects for both IL-1α and IL-1β have been demonstrated in various mouse models, and several studies suggest that IL-1α and IL-1β can significantly enhance T-cell mediated antitumor immunity.

**IL-1α and IL-1β are Natural Adjuvants for Antitumor Immunity**

Although structurally quite different, mature IL-1α and IL-1β mediate their functions by binding to the same IL-1 receptor I (IL-1RI) which is present on the surface of most cells. Importantly, IL-1RI share with Toll-like receptors (TLRs) a common intracellular signaling pathway, which leads to activation of the nuclear factor κB (NFκB) and hence to the transcription of several pro-inflammatory cytokines, such as IL-1α, IL-1β, IL-6 and TNFα (Fig. 3). Therefore, IL-1α and IL-1β function within positive feedback loops during inflammation. Because of the common intracellular signaling pathway, IL-1α and IL-1β operate as natural adjuvants, thus mimicking the detection of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by TLRs (Fig. 3). Early work by Ralph Steinman and coworkers revealed that IL-1α can amplify the function of dendritic cells and thereby enhance T-cell dependent immunity. It was also shown that IL-1α can be used as an adjuvant to trigger the clonal expansion and differentiation of antigen-activated Th cells, as well as Th-mediated antibody production. Several studies investigated the potential of IL-1α and IL-1β as adjuvants for cancer vaccines. In a mouse model of lung cancer, a vaccine was made by combining irradiated cancer cells with IL-1α or IL-1β. IL-1β was successfully used as an adjuvant, together with sonicated cancer cells, to induce tumor-specific immunity against MOPC104E plasmacytoma and MethA sarcoma in mice. Finally, an IL-1RI-binding peptide derived from IL-1β was shown to augment antitumor immune responses induced by protein and DNA vaccines against 38C13 mouse B-cell lymphoma. Altogether, these data suggest that IL-1α and IL-1β, as whole proteins or biologically active fragments, may represent potent adjuvants for cancer vaccines.

**Cancer-Suppressive Functions of IL-6**

The pro-inflammatory cytokine IL-6 exerts multiple functions, including the stimulation of B and T cells as well as the production of acute-phase proteins by hepatocytes. IL-6 plays an essential role in antibacterial and antiviral immunity. IL-6 is a B-cell growth factor, which stimulates proliferation of normal and malignant B cells. In several types of human cancer, such as multiple myeloma, B-cell lymphoma and lung cancer, high IL-6 serum levels have been associated with short patient survival, supporting cancer-promoting effects for IL-6. However, a number of studies documented cancer-suppressive properties of IL-6 (Fig. 4). Treatment of mice with IL-6 induced the regression of established micrometastases in the liver and lungs of sarcoma and colon adenocarcinoma, in a process that required both CD4+ and CD8+ T cells. In mice inoculated with acute myeloid leukemia cells, IL-6 injections inhibited tumor development and increased survival. Murine B16 melanoma cells transfected with IL-6 became less tumorigenic, and mice with established melanoma were successfully treated with recombinant IL-6. Combined treatment with IL-6 and cyclophosphamide efficiently cured mice bearing advanced pulmonary metastases from fibrosarcoma. Immunization of mice with IL-6-transfected Lewis lung carcinoma cells induced high levels of tumor-specific cytotoxic T cells and functioned as an efficient antitumor immunity苞.
prophylactic and therapeutic cancer vaccine. Fibrosarcoma cells transduced with IL-6 exhibited reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Similar findings were obtained in rats, in which IL-6-transduced glioma cells showed attenuated tumorigenicity and functioned as an efficient vaccine against intracranial glioma. In mice bearing B16F10 melanoma treated with the synthetic triacylated lipopeptide PamC3SK4 (a TLR2 agonist), mast cell-derived IL-6 was essential for the inhibition of tumor growth. Endogenous IL-6 reportedly increases CD8+ T cell trafficking to the tumors in mice with B16 melanoma treated with systemic thermal therapy combined with adoptive T cell transfer. In humans, IL-6 has been shown to suppress the proliferation of acute myeloid leukemia and B-chronic lymphocytic leukemia cells, revealing an inhibitory effect of IL-6 on some human B-cell malignancies. Moreover, in vitro studies on human melanoma demonstrated that exposure to IL-6 inhibits the growth of early-stage but not advanced stage melanoma cells. Thus, IL-6 has been shown to inhibit in vitro proliferation of several types of human cancer cells, and cancer-suppressive effects of IL-6 have been demonstrated in vivo, in several animal models.

**Cancer-Suppressive Functions of TNFα**

TNFα is a pleiotropic pro-inflammatory cytokine typically produced by activated macrophages. The effects of TNFα are mediated by two distinct receptors: TNFα receptor 1 (TNFR1) and TNFR2. TNFR1 is present on most cell types and accounts for the majority of pro-inflammatory (through induction of NFκB) and apoptotic effects of TNFα. TNFR2 is present on the surface of lymphocytes and promotes activation and proliferation. TNFα has an impact on all aspects of T-cell biology including T-cell proliferation, co-stimulation and survival (reviewed in ref. 71). A number of studies documented tumor-promoting effects of TNFα (reviewed in ref. 72). For example, TNFα-deficient mice were less susceptible to carcinogen-induced papilloma, a benign epithelial tumor, suggesting that TNFα may promote skin cancer development. In chronic lymphocytic leukemia, patients with high plasma levels of TNFα had a significantly shorter survival rate. However, a large body of literature has revealed the cancer-suppressive properties of TNFα (Fig. 5). TNFα was first identified as an endotoxin-induced serum factor produced by macrophages that caused hemorrhagic necrosis of MethA sarcoma and other solid tumors. The hemorrhagic reaction apparently resulted from the destruction of tumor blood vessels. Experiments with T-cell deficient mice revealed that TNFα does not solely damage tumor blood vessels, but it also stimulates tumor-specific T cells. Furthermore, in vitro studies demonstrated that TNFα is directly cytotoxic for various human cancer cell lines such as melanoma, breast, cervix and colon carcinoma. TNFα rendered human monocytes cytotoxic against a murine fibrosarcoma cell line in vitro. Synergistic in vivo antitumor effects against the murine MCA-106 sarcoma were reported for the combined administration of TNFα and IL-2. J558L myeloma cells transplanted with TNFα were efficiently eliminated in mice, and it was proposed that TNFα mediates recruitment of NK cells to the peritoneum to eliminate MHC Class I-negative cancer cells; is important for priming, proliferation and recruitment of tumor-specific CD8+ T cells; stimulates antigen-presenting cell functions and cytokine production; and it increases vascular permeability leading to improved penetration of chemotherapeutics in the tumor tissue.
would function by recruiting and activating macrophages. In a follow-up study, rejection of TNFα-transfected J558L myeloma cells was shown to be partly dependent on CD8+ T cells. In a mouse model for T-cell lymphoma, an opposing effect of TNFα on tumor growth was reported: TNFα induced the rejection of solid tumors but promoted the formation of hepatic metastases. TNFα was essential for recruitment of NK cells to the peritoneum to eliminate MHC Class I-negative RMA-S lymphoma cells. TNFα-deficient mice were more susceptible than wild-type mice to sarcoma induction with the carcinogen methylcholanthrene. TNFα was critical for the prevention of pancreatic tumors in a mouse model of cancer immunosurveillance mediated by tumor-specific CD8+ T cells. In this model, TNFα was important for the priming, proliferation and recruitment of tumor-specific CD8+ T cells. Importantly, this study identified the critical roles of TNFR1 on antigen-presenting cells and TNFR2 on T cells for successful antitumor immunity.

Using TNFα for Cancer Immunotherapy in Humans

On the basis of the experimental evidence described above, TNFα is currently being used for human cancer immunotherapy (reviewed in ref. 86). A main limitation for clinical application of TNFα has been the toxicity that is associated with systemic administration. To circumvent this problem, isolated limb perfusion was performed and successful treatment of advanced melanoma and soft tissue sarcoma was achieved. During isolated limb perfusion, TNFα has a double effect on the tumor-associated vasculature: (1) TNFα increases vascular permeability leading to improved penetration of chemotherapy within the tumor tissue, and (2) TNFα selectively kills angiogenic endothelial cells resulting in tumor vessel destruction. Several strategies are being developed to allow for the systemic administration of TNFα while limiting toxicity to the patient, in particular by that targeted delivery of TNFα to tumors.

Pro-Inflammatory Cytokines Synergize With Other Cytokines to Fight Cancer

The biological effects of a given cytokine are strongly dependent on the cytokine milieu. In cancer immunology, it is well documented that pro-inflammatory cytokines may synergize with other cytokines against neoplastic cells. For example, TNFα and IFNγ acted in synergy to block the in vitro proliferation of murine Lewis lung carcinoma and B16 melanoma cells. Similarly, treatment of mice bearing B16 melanoma with both TNFα and IFNγ was more efficient than the administration of either cytokine alone. Combined treatment with IL-1β and IL-2 generated a synergistic T-cell dependent antitumor response against highly metastatic Friend leukemia in mice. Mice with established subcutaneous MCA-106 sarcoma tumors were cured by the combinatorial treatment with TNFα and IL-6, revealing a synergistic antitumor effect of these two pro-inflammatory cytokines. In vitro studies demonstrated that a combination of IFNγ and IL-1β induced necrosis of murine L929 fibrosarcoma cells. Combined treatment of human papillary thyroid carcinoma cell lines with IL-1β and IFNγ efficiently inhibited proliferation and invasiveness. TNFα and IFNγ synergized to mediate in vitro cytotoxicity against a large number of human cell lines including breast, cervix and colon carcinoma cells. Finally, TNFα and IFNγ were shown to synergize to induce the tumoricidal activity of murine macrophages. Thus, although pro-inflammatory cytokines may be directly cytotoxic to cancer cells, synergistic interactions with other cytokines are likely to be very important for successful antitumor immunity. Importantly, the combination of pro-inflammatory cytokines with Th1 cytokines like IL-2 and IFNγ seems to be particularly beneficial for cancer therapy.

A Model for How Inflammation May Either Suppress or Promote Cancer

From the literature overviewed above, it is apparent that inflammatory cells and pro-inflammatory cytokines not only can promote but also may suppress cancer in various settings. Therefore, cancer-related inflammation cannot be generalized as solely detrimental or beneficial. To reconcile conflicting data, we propose that, among all the existing types of inflammation, certain types are cancer-suppressive while others may be cancer-promoting. Based on our own findings and evidence from the literature, we suggest that inflammation driven by tumor-specific Th1 cells may be particularly beneficial against cancer (Fig. 6, left). During Th1-driven cancer-suppressive inflammation, tumor-specific Th1 cells collaborate with tumor-infiltrating M1 macrophages to efficiently recognize and eliminate malignant cells. M1 macrophages function as efficient antigen-presenting cells that process and present cancer antigens to tumor-specific CD4+ and CD8+ T cells in the tumor. Th1 cells are characterized by the production of IFNγ and experiments with gene-targeted mice demonstrated that IFNγ is critical for cancer immunosurveillance. IFNγ is a potent macrophage-activating factor, stimulating their tumoricidal activity and the acquisition of a M1 phenotype. M1 macrophages are cancer-suppressive in vitro and in vivo, and produce pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, TNFα), the Th1-polarizing cytokine IL-12, as well as IFNγ-induced chemokines (CXCL9/MIG, CXCL10/IP-10 and CXCL11/I-TAC). In a Th1 environment, pro-inflammatory cytokines may play essential roles in cancer elimination, e.g., by recruiting T cells and macrophages from the circulation and by stimulating leukocyte tumoricidal functions (Fig. 6, left). Pro-inflammatory cytokines synergize with Th1-derived cytokines (IL-2 and IFNγ) to fight cancer. Similarly, CXCL9, CXCL10 and CXCL11 may participate in antitumor immunity by blocking tumor angiogenesis and by recruiting Th1 cells, CD8+ T cells and NK cells to the tumor site. In contrast to Th1-driven cancer-suppressive inflammation, other types of inflammation may instead promote cancer development (reviewed in refs. 1–4). In the absence of sufficient numbers of tumor-specific Th1 cells, pro-inflammatory cytokines (IL-1α, IL-1β, IL-6, TNFα) may participate in cancer development, progression and metastasis, for instance by stimulating angiogenesis and cancer cell growth, and by increasing vascular permeability (Fig. 6, right).
Inducing Inflammation to Treat Cancer

On the basis of the model described above, we propose that immunotherapy protocols that induce or promote an inflammatory reaction driven by tumor-specific Th1 cells may be particularly efficient at eradicating cancer. PAMPs tend to induce Th1-type inflammatory immune responses upon binding to receptors such as TLRs on immune cells. Several reports document successful cancer immunotherapy protocols based on inducing inflammation with PAMPs. Early studies in mice revealed that treatment with double-stranded RNA or lipopolysaccharide induced lymphocyte-mediated rejection of L5178Y lymphoma and FS6 fibrosarcoma. More recently, mice with C26 colon carcinoma and B16F0 melanoma have been successfully treated with a combination of anti-IL-10-receptor antibodies and the intratumoral injection with CpG, a TLR-9 ligand. This treatment has been show to stimulate the production of IL-12 by tumor-infiltrating dendritic cells, thereby enhancing T-cell mediated antitumor immunity. In humans, the intravesical application of the bacterium Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is an efficient and widely-used treatment for superficial bladder cancer (reviewed in ref. 110). Moreover, imiquimod, an imidazoquinoline compound which activates immune cells via TLR7, is an effective treatment for several human malignancies such as superficial basal cell carcinoma, actinic keratosis and vulvar intraepithelial neoplasia. Collectively, these data suggest that inducing Th1-type inflammation may represent an efficient strategy to achieve successful cancer immunotherapy.

Concluding Remarks

Treating cancer with anti-inflammatory drugs. This new therapeutic approach is based on the well-documented cancer-promoting aspects of inflammation. The model that we present here suggests that caution should be taken. Anti-inflammatory drugs that dampen ongoing cancer-suppressive Th1 inflammation in patients may potentially exacerbate, rather than cure, established malignancies.

Anti-inflammatory drugs and cancer risk. Novel anti-inflammatory drugs that specifically block key inflammatory molecules, e.g., pro-inflammatory cytokines, have been developed. These drugs have revolutionized the treatment of several chronic inflammatory diseases such as rheumatoid arthritis. Moreover, evidence suggests that some non-steroidal anti-inflammatory drugs, e.g., aspirin, may lead to a reduced risk for cancer. However, anti-inflammatory drugs may potentially weaken...
cancer immunosurveillance. Therefore, it is advisable that patients receiving long-term treatment with novel anti-inflammatory drugs should be followed up for cancer development.

**Acute vs. chronic inflammation.** It has been suggested that acute inflammation protects against cancer, whereas chronic inflammation promotes cancer. This hypothesis is based on the observation that acute inflammation may cure cancer, whereas several chronic inflammatory diseases predispose to cancer.

However, there are indications that chronic inflammation may not always be detrimental. For several types of human cancer, a strong inflammatory response in the primary tumor, as defined by a high density of infiltrating T cells and macrophages, has been shown to represent an independent predictor for longer patient survival. Because a detectable tumor takes a long time to develop, tumor-associated inflammation, unless treatment-induced, should arguably be defined as chronic inflammation. This implies that a strong chronic inflammation in tumors may repress rather than promote cancer, therefore representing an example of beneficial chronic inflammation against cancer.

**Synergy between chemotherapy and immunotherapy.** Although chemotherapy is generally considered immunosuppressive, several reports revealed that it may improve cancer immunotherapy. For instance, treatment of mice with ABI mesothelioma with the cytokine analog gemcitabine significantly enhanced immunotherapy with a viral cancer vaccine or with anti-CD40 monoclonal antibodies. In humans, chemotherapy of melanoma patients with the DNA alkylating agent dacarbazine was shown to improve the CD8+ T-cell response to a cancer vaccine. Mouse studies revealed that inflammatory mediators induced by chemotherapy may stimulate antitumor immunity. Thus, induction of a strong inflammation in tumors is likely to be a main component of the observed synergy between chemotherapy and immunotherapy.

**Acknowledgments**

We thank Kristina Berg Lorvik, Inger Oynebråten, Ranveig Braathen and Peter O. Hofgaard for critical reading of the manuscript. This work was supported by grants from Helse Sør-Øst, the Research Council of Norway, the Norwegian Cancer Society, Andrine og Hans Gysler Berg fund and S. G. Sønneland foundation. A.C. wrote the manuscript. O.A.W.H. and B.B. contributed in writing the manuscript. O.A.W.H. prepared the figures.

**References**

1. Balckwell F, Mantovan A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45; PMID:11229684; http://dx.doi.org/10.1016/S0140-6736(00)09466-0.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322.
3. Mantovan A, Allavena P, Sica A, Balckwell F. Cancer-related inflammation. Nature 2008; 454:436-44; PMID:18659314; http://dx.doi.org/10.1038/nature07205.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20104048; http://dx.doi.org/10.1016/j.cell.2010.01.025.
5. Pellinieni TT, Iijala K, Markila P, Pulkkii K, Rajamaki A, Tienhaara A, et al.; Finnish Leukemia Group. Immunoregulatory interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 1995; 85:765-71; PMID:7530507.
6. Petri HA, Cabañillas F, Talpaz M, Tucker SL, Seymour JF, Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 1997; 127:186-94; PMID:9242253.
7. Martin F, Santolaria F, Batista N, Milena A, González-Reimers E, Brito MJ, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytkine 1999; 11:80-6; PMID:10888883; http://dx.doi.org/10.1006/cyto.1998.0398.
8. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48:526-35; PMID:11247898; http://dx.doi.org/10.1136/gut.48.4.526.
9. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10:403-14; PMID:20495574; http://dx.doi.org/10.1038/nrct.2857.
10. Ekström K, Hjalgrim H, Brandt L, Baeklund E, Klarskov L, Ekbom A, et al. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 2003; 48:963-70; PMID:12687538; http://dx.doi.org/10.1002/art.10939.
28. Yoshida N, Abe H, Ohkuki T, Wakiita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol 2006; 28:1089-98; PMID:16596224.

29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:515-8; PMID:17085531; http://dx.doi.org/10.1126/science.1121939.

30. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29:1949-55; PMID:22438302; http://dx.doi.org/10.1200/JCO.2010.30.5037.

31. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. Plast Reconstr Surg 2005; 2:e284; PMID:16124834; http://dx.doi.org/10.1097/01.PRS.0000182284.00432.CCR-06-2073.

32. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zaneretti KA, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the IRE1alpha tumor suppressor. Cancer Cell 2006; 9:109-111; PMID:16904609; http://dx.doi.org/10.1016/j.ccr.2006.06.016.

33. Kristensen VN, Vanke CJ, Ursini-Siegel J, Van Loo P, Northfelt DW, van der Burg SH, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and intercellular signaling. Proc Natl Acad Sci USA 2012; 109:2802-7; PMID:21908711; http://dx.doi.org/10.1073/pnas.1108871108.

34. Shimura S, Yang G, Bhatia T, Frese K, Basset A, Keppens D, et al. IL-1 is required for cytokine-induced CD8+ T cell proliferation and cytokine-driven survival of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res 2000; 60:5857-61; PMID:11059785.

35. Welsh TJ, Green RH, Richardson D, Waller DA, Green RM, Johnson D, et al. Differential effects of IL-1 and IL-2 on tumorigenicity patterns of human circulating NK cells and T lymphocytes: synergistic effects of IL-1 and IL-2. J Immunol 1987; 139:443-51; PMID:3110271.

36. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R, et al. High macrophage infiltration along the tumor front correlates with improved survival in non-small-cell lung cancer. J Clin Oncol 2012; 30:5857-61; PMID:21908711; http://dx.doi.org/10.1200/JCO.2005.01.4910.

37. Ben-Sasson SZ, Hu-Li J, Quiel J, Caucheteaux S, Ratner M, et al. NY-ESO-1 cancer-testis antigen induces CD8+ T cells that display short-term intercellular lalpha expression. Cancer Res 1999; 59:1029-35; PMID:10070959.

38. Voronov E, Ofori D, Zeng A, Cagnano E, Ofir R, Dobkin M, et al. Interleukin-1 and interleukin-1 alpha against murine syngeneic tumors. J Immunol 1997; 159:591-8; PMID:9181072; http://dx.doi.org/10.1126/jem.159.2.887.

39. Lee PP. Profile of immune cells in axillary lymph nodes based on a unique immune response signature of the IRE1alpha tumor suppressor. Cancer Cell 2006; 9:109-111; PMID:16904609; http://dx.doi.org/10.1016/j.ccr.2006.06.016.

40. Lipsky PE, Thompson PA, Rosenwasser LJ, Dinarello CA. The role of interleukin 1 in human b cell activation: inhibition of b cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocyte pyrogen. J Immunol 1983; 130:2708-14; PMID:6222114.
87. Crispe IN, Tateyama H, Nakamura Y, Arnot C, Burke SA, et al. Tumor necrosis factor-alpha is resistant to skin carcinogenesis. Proc Natl Acad Sci USA 1986; 83:13791-6; PMID:3918036; http://dx.doi.org/10.1073/pnas.83.23.13791.

90. Jung M, Diminich A, Velena A, Dritschilo A. Combining radiation therapy with intestinal radiation-inducible TNFα expression for locoregional cancer treatment. Cancer Gene Ther 2011; 18:189-95; PMID:21092099; http://dx.doi.org/10.1038/cgt.2010.69.

95. Hori K, Ehrke MJ, Mace K, Mihich E. Effect of anti-TNF antibodies on adoptive T cell immunity in mice. J Exp Med 1996; 184:981-92; PMID:9604358; http://dx.doi.org/10.1084/jem.184.8.981.

100. Pace JL, Russell SW, et al. Anti-tumor effects of interleukin-2 and recombinant tumor necrosis factor in mice. Cancer Res 1987; 47:2563-70; PMID:1910856.

105. Belardelli F, Ciolfi V, Testa U, Montesano E, Bulgarini D, Proietti E, et al. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors. Int J Cancer 1989; 44:1108-13; PMID:2933576.

108. Parr I, Wheeler E, Alexander P. Similarities of the anti-tumor activities of endotoxin, lipid A and double-stranded RNA. Br J Cancer 1973; 27:370-89; PMID:4713170; http://dx.doi.org/10.1038/bjc.1973.74.

112. Cebon J, Di Chiara D, Vassallo AM, Ferrara GM, Grant WM, Selby PL. Anti-tumour effects of interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer 1989; 25:931-8; PMID:2626801; http://dx.doi.org/10.1016/0277-5379(89)90011-3.

115. Blanckstein T, Qin ZH, Uberla K, Müller W, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991; 173:1047-52; PMID:20229199; http://dx.doi.org/10.1084/jem.1991.173.5.1047.

120. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin-2, interleukin-4, interleukin-7, tumor necrosis factor, or interferon gene. Proc Natl Acad Sci USA 1993; 90:2774-8; PMID:6468888; http://dx.doi.org/10.1073/pnas.90.8.2774.

125. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998; 188:1191-9; PMID:9802973; http://dx.doi.org/10.1084/jem.188.8.1191.

130. Shanakara Y, IIdaka H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNγamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; PMID:11235675; http://dx.doi.org/10.1038/35074122.

135. Schreiber RD, Pace JL, Russell SW, Altman A, Katz DH. Macrophage-activating factor produced by a T cell hybridoma: physiological and biosynthetic resemblance to gamma-interferon. J Immunol 1983; 131:826-32; PMID:6408190.

140. Pace JL, Russell SW, Schreiber RD, Altman A, Katz DH. Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. Proc Natl Acad Sci USA 1983; 80:5788-92; PMID:6407020; http://dx.doi.org/10.1073/pnas.80.12.5788.

145. Schulz RM, Kleinhanschulz WJ. Functional identity between murine gamma interferon and macrophage activating factor. Nature 1983; 305:239-40; PMID:66141244; http://dx.doi.org/10.1038/305239a0.

150. Sgardali C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, et al. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996; 93:13791-6; PMID:8943014; http://dx.doi.org/10.1073/pnas.93.24.13791.

155. Aareberg DA, Dalkin SL, Polverini PJ, Morris JB, Budnick MD, Glass MC, et al. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184:981-92; PMID:9604358; http://dx.doi.org/10.1084/jem.184.8.981.

160. Geese JK, Rich P, Pandya A, Gross K, Andrews K, Ginkel A, et al. In situ immunodilation for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:399-80; PMID:12196749; http://dx.doi.org/10.1016/S0190-9622(02)01265.1.
113. Lebwohl M, Dinelli S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50:714-21; PMID:15097955; http://dx.doi.org/10.1016/j.jaad.2003.12.010.

114. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008; 358:1465-73; PMID:18385408; http://dx.doi.org/10.1056/NEJMoa072685.

115. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170:4905-13; PMID:12734333.

116. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-6; PMID:12907622.

117. Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009; 124:130-9; PMID:18839429; http://dx.doi.org/10.1002/ijc.23886.

118. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622.